### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor : Attorney Docket No. 2004-1016A

Masayo HIGASHIYAMA : Confirmation No. 2612

Serial No. 10/500,354 : Group Art Unit 1611

Filed June 30, 2004 : Examiner Barbara S. Frazier

AQUEOUS LIQUID PREPARATIONS AND LIGHT-STABILIZED AQUEOUS LIQUID

**PREPARATIONS** 

Mail Stop: AF

# **AMENDMENT AFTER FINAL REJECTION**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir/Madam:

In response to the Office Action of April 30, 2014, please amend the above-identified application as follows:



## **AMENDMENTS TO THE CLAIMS**

1. (Currently Amended) An aqueous liquid preparation consisting essentially of, in an aqueous solution, an active ingredient consisting of (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino] butyric acid or a pharmacologically acceptable acid addition salt thereof, and thereof; a water-soluble metal chloride in a light-stabilizing effective amount, amount; water; and optionally at least one material selected from the group consisting of a buffer, a preservative, a chelating agent, and a flavor; wherein the metal chloride has a concentration selected from the range of a lower limit concentration of 0.2 w/v% and an upper limit concentration of 1.2 w/v%.

## 2. (Cancelled)

**3.** (**Previously Presented**) The aqueous liquid preparation of claim 1, wherein the metal chloride is at least one kind selected from sodium chloride, potassium chloride and calcium chloride.

### 4. (Cancelled)

- **5.** (**Previously Presented**) The aqueous liquid preparation of claim 1, which is an acid addition salt of (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid.
- **6. (Original)** The aqueous liquid preparation of claim 5, wherein the acid addition salt is monobenzenesulfonate.
- 7. (Previously Presented) The aqueous liquid preparation of claim 1, wherein the aqueous liquid preparation has a pH in the range of 4-8.5.
- 8. (Previously Presented) The aqueous liquid preparation of claim 1, which is an eye drop.
- **9.** (Previously Presented) The aqueous liquid preparation of claim 1, which is a nasal drop.



# **10-11.** (Cancelled)

- 12. (Previously Presented) The aqueous liquid preparation of claim 1, wherein the metal chloride is at least one kind selected from alkali metal chlorides and alkaline earth metal chlorides.
- 13. (Currently Amended) An aqueous eye drop consisting essentially of of: (a) an active ingredient consisting of (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid addition salt thereof, which is light-stabilized with: (b) a water-soluble metal chloride, chloride; (c) sodium dihydrogen phosphate buffer; (d) a preservative; (e) water; and optionally (f) disodium edetate; wherein the metal chloride has a concentration selected from the range of a lower limit concentration of 0.2 w/v% and an upper limit concentration of 1.2 w/v%.
- **14.** (**Previously Presented**) An aqueous liquid preparation consisting of, in an aqueous solution, an active ingredient consisting of (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino] butyric acid or a pharmacologically acceptable acid addition salt thereof, a water-soluble metal chloride in a light-stabilizing effective amount, wherein the metal chloride has a concentration selected from the range of a lower limit concentration of 0.2 w/v% and an upper limit concentration of 1.2 w/v%, benzalkonium chloride, sodium dihydrogenphosphate dihydrate, sodium hydroxide and water.
- **15.** (Currently Amended) The aqueous eye drop of claim 13, wherein:
- (a)-(i) the (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or the pharmacologically acceptable acid addition salt thereof is (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid monobenzenesufonate;
  - (b) (ii) the water-soluble metal chloride is sodium chloride; and
- (e) (iii) the sodium chloride has a concentration selected from the range of a lower limit concentration of 0.2 w/v% and an upper limit concentration of 0.8 w/v%.



### **REMARKS**

Further and favorable reconsideration is respectfully requested in view of the foregoing amendments and the following remarks.

### I. Claim Amendments

Entry of the amendments is proper under 37 CFR §1.116, because the amendments place the application in condition for allowance and do not raise any new issue requiring further search and/or consideration. The amendments are necessary and were not earlier presented, because they are made in response to arguments raised in the final rejection. In addition, the amendments are submitted with a request under AFCP 2.0. Entry of the amendments is thus respectfully requested.

Claims 1, 3, 5-9 and 12-15 are pending in this application.

Claim 14 has been allowed.

Claims 1 and 13 have been amended to replace "consisting essentially of" with "consisting of".

Claim 1 has also been amended to include one or more "optional" materials selected from the group consisting of "a buffer, a preservative, a chelating agent, and a flavor". Support for these optional materials can be found on page 6, lines 4-18 of the specification.

Claim 13 has also been amended to include "sodium dihydrogen phosphate buffer", "a preservative", "water", and, optionally, "disodium edetate". Support for these amendments can be found on page 6, lines 4-16, Tables 2 and 3, and Examples 1-3 and 8-12.

Claim 15 has been amended to make minor editorial changes in view of the amendments to claim 13.

# II. Telephone Interviews

Applicant appreciates the courtesies extended to Applicant's attorney by Examiner Frazier during the telephone interviews held April 25, 2014, May 6, 2014 and May 22, 2014.

During the first interview, Applicant's attorney pointed out that the Office Action issued April 23, 2014 does not list claim 14 as allowed. The Examiner agreed to issue the new outstanding Office Action to confirm that claim 14 has been allowed.



During the second interview, Applicant's attorney presented the amendments to claims 1, 13 and 15 mentioned above, and explained that changing "consisting essentially of" to "consisting of" should overcome the rejection under 35 U.S.C. § 103(a). Further, Applicant's attorney pointed out that claim 14, which recites "consisting of", has been allowed. Examiner Frazier provisionally agreed that the amendments over the rejection, but stated that further consideration and/or search are necessary before she could confirm allowance of the claims. The Examiner also requested Applicant submit the amendments under AFCP 2.0.

During the third telephone interview, the Examiner confirmed that her Supervisor agrees that the amendments appear to overcome the rejection.

Accordingly, Applicant has amended claims 1, 13 and 15 as discussed during the interview, and submits the amendments under AFCP 2.0.

# III. Claim Rejection Under 35 U.S.C. § 103

The Examiner has rejected claims 1, 3, 5-9, 12, 13 and 15 under 35 U.S.C. § 103(a) as being unpatentable over Lehmussaari et al. (US 5,795,913) in view of Kita et al. (US 6,307,052), and optionally further in view of Araki et al. (WO 01/80858; US 2003/0139436). As applied to the amended claims, Applicant respectfully traverses the rejection.

Claims 1 and 13 has been amended to recite the transitional phrase "consisting of". The transitional phrase "consisting of" excludes any element, step, or ingredient not specified in the claim (see MPEP 2111.03, citing *In re Gray*, 53 F.2d 520, 11 USPQ 255 (CCPA 1931)).

The composition of Lehmussaari et al. requires the inclusion of an ion sensitive, hydrophilic polymer having viscosity, such as <u>Carbopol</u>, to control the formation of the polymer film on the cornea of the eye, and each of the reference's examples contain Carbopol (please see col. 2, line 57 to col. 3, line 6, and the Examples).

However, claims 1 and 13 do not recite "Carbopol". As a result, this ingredient is excluded from the aqueous liquid preparation of claim 1 and the eye drop of claim 13.

The references fail to disclose or suggest the aqueous liquid preparation of claim 1 or the eye drop of claim 13, consisting of the ingredients recited therein.

Therefore, as agreed during the interview, claims 1 and 13 would not have been obvious over the combination of references.



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

# **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

# API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

# **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

